Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates for use in the hospital setting primarily in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever in adults and children. OFIRMEV is targeted at anesthesiologists, surgeons, certified registered nurse anesthetists, emergency medicine physicians, intensivists, internists, hospitalists, obstetricians, and other physicians throughout the hospital, as well as hospital-based pharmacists. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Address
Suite 200, 12481 High Bluff Drive
SAN DIEGO, CA 92130
United States
SAN DIEGO, CA 92130
United States
Website
www.cadencepharm.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -23.96% | -161.35% |
| Operating margin | -20.10% | -152.79% |
| EBITD margin | - | -129.87% |
| Return on average assets | -32.06% | -61.97% |
| Return on average equity | -75.95% | -96.90% |
| Employees | 211 |
No comments:
Post a Comment